Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | PLK4 | O00444 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25691074 | 0.93 | CRBN (0.54) | ARCRBNDDB1MAPTALDH1A1 | |
| SCHEMBL25691432 | 0.89 | AR (0.48) | ARCRBNDDB1IKZF3PLK4 | |
| SCHEMBL25691416 | 0.88 | CRBN (0.47) | ARCRBNDDB1MAPTALDH1A1 | |
| SCHEMBL23134592 | 0.81 | CRBN (0.56) | ARCRBNDDB1ALDH1A1IKZF3 | |
| SCHEMBL29822127 | 0.81 | CRBN (0.57) | ARCRBNDDB1MEN1KMT2A | |
| SCHEMBL23117907 | 0.81 | CRBN (0.57) | ARCRBNDDB1MEN1KMT2A | |
| SCHEMBL25691403 | 0.81 | CRBN (0.53) | CRBNDDB1MAPTALDH1A1L3MBTL1 | |
| SCHEMBL25691424 | 0.80 | CRBN (0.45) | ARCRBNDDB1PLK4 | |
| SCHEMBL22661504 | 0.79 | AR (0.54) | ARCRBNDDB1IKZF3PLK4 | |
| SCHEMBL25691418 | 0.77 | CRBN (0.47) | ARCRBNDDB1PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150973-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, UTS2R, ESRRA | AR 1/4885CRBN 1041/4885DDB1 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.